RC
KURA icon

Rangeley Capital’s Kura Oncology KURA Stock Holding History

Rangeley Capital’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$823K Sell
101,220
-1,680
-2% -$14.4K 0.8% 39
2025
Q4 		$1.07M Sell
102,900
-17,100
-14% -$179K 0.89% 36
2025
Q3 		$1.06M Buy
120,000
+4,000
+3% +$28.5K 0.92% 26
2025
Q2 		$669K Buy
+116,000
New +$711K 0.8% 27

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rangeley Capital's KURA Position: Q1 2026 in Review

Rangeley Capital reduced its Kura Oncology (KURA) stake by 1.6% in Q1 2026, selling an estimated $14.4K and leaving 101,220 shares worth $823K. The position accounts for 0.8% of the portfolio, ranked #39.

Rangeley Capital first reported a position in KURA in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.07M in Q4 2025. 220 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • Rangeley Capital held 101,220 shares of Kura Oncology worth $823K as of Q1 2026.
  • Rangeley Capital sold 1,680 Kura Oncology shares in Q1 2026, an estimated $14.4K.
  • Kura Oncology made up 0.8% of Rangeley Capital's portfolio in Q1 2026, its #39 holding.
  • Rangeley Capital first reported a position in Kura Oncology in Q2 2025 and has held it in 4 quarters since.
  • Rangeley Capital's Kura Oncology position peaked at $1.07M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.